Development of the composition of chewable tablets based on dry extracts for urological use

Abstract

Cystitis is an inflammatory disease of the urinary bladder, characterized by an acute or chronic course. The pathology has gender specificity: the incidence among women is 20–25%, while in men this figure does not exceed 0.5%, according to epidemiological data. There is a steady trend towards an increase in the prevalence of this nosology, which, in particular, is due to adverse environmental conditions (long stay in rooms with low temperature), which is especially relevant in today’s conditions. A critical factor in the effectiveness of cystitis therapy is the speed of achieving a clinical effect. In view of this, chewable tablets (CT) are a promising dosage form. The advantage of this form is the optimization of the drug’s pharmacokinetic profile due to the disintegration of the tablet directly in the oral cavity. Higher bioavailability of active substances is ensured compared to traditional oral forms, which allows reducing the time of onset of therapeutic effect